| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 5.209 | 31.044 | 38.045 | 34.535 | 39.765 | 45.041 | 29.877 | 6.465 | 0 | 5.005 |
| Total Income - EUR | 5.242 | 32.503 | 38.102 | 34.603 | 39.771 | 45.055 | 29.892 | 6.465 | 0 | 5.014 |
| Total Expenses - EUR | 8.829 | 34.564 | 39.507 | 36.641 | 39.649 | 44.304 | 31.364 | 6.609 | 440 | 10.254 |
| Gross Profit/Loss - EUR | -3.586 | -2.061 | -1.404 | -2.038 | 122 | 751 | -1.472 | -144 | -440 | -5.240 |
| Net Profit/Loss - EUR | -3.744 | -2.684 | -1.785 | -2.384 | -276 | 334 | -1.771 | -338 | -440 | -5.240 |
| Employees | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 |
Check the financial reports for the company - Biocrislin Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 3.411 | 2.095 | 883 | 0 | 0 | 0 | 491 | 355 | 217 | 79 |
| Current Assets | 8.771 | 11.081 | 12.081 | 11.501 | 10.058 | 8.689 | 6.091 | 3.300 | 4.047 | 1.572 |
| Inventories | 6.270 | 8.042 | 8.920 | 8.594 | 7.990 | 6.352 | 3.957 | 648 | 647 | 0 |
| Receivables | 2.312 | 2.476 | 2.288 | 1.933 | 1.520 | 1.829 | 1.986 | 1.922 | 1.974 | 1.538 |
| Cash | 189 | 563 | 873 | 974 | 548 | 508 | 148 | 729 | 1.427 | 34 |
| Shareholders Funds | -3.699 | -6.345 | -8.023 | -10.260 | -10.337 | -9.807 | -11.361 | -11.734 | -12.138 | -17.310 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 16.717 | 20.350 | 21.802 | 22.561 | 20.395 | 19.152 | 18.583 | 15.388 | 16.402 | 18.961 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4773 - 4773" | |||||||||
| CAEN Financial Year |
5610
|
|||||||||
Comments - Biocrislin Srl